John Eikelboom
Overview
Explore the profile of John Eikelboom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
188
Citations
9890
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yao L, Eikelboom J, Macnab A, Yu Z, Cao Y, Wei W, et al.
Adv Biol (Weinh)
. 2025 Feb;
:e2400481.
PMID: 39950362
The prevailing focus of lifespan health research has predominantly centered on "healthy aging". This oversight may hinder the understanding of health across the lifespan, as disorders in earlier stages can...
2.
Teixeira M, Barroso W, Brandao A, Sousa A, Esporcatte R, de Borba M, et al.
Glob Heart
. 2025 Jan;
20(1):6.
PMID: 39867664
Background: Emerging evidence suggests that spirituality improves patient outcomes, however, this has undergone only limited evaluation in randomized trials. Hypertension is a major cause of cardiovascular morbidity and mortality worldwide....
3.
Carlin S, Chan N, Godoy A, Bhagirath V, Hirsh J, Eikelboom J
J Thromb Haemost
. 2024 Nov;
PMID: 39581233
Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) for stroke prevention in many patients with atrial fibrillation, but VKAs may still be preferred in some situations. We use...
4.
McClure G, Eikelboom J
Expert Rev Hematol
. 2024 Nov;
17(12):877-884.
PMID: 39560465
Introduction: Patients undergoing revascularization of the lower extremities have unacceptably high rates of major adverse cardiac and limb events despite the routine use of antiplatelet therapy. Optimization of antithrombotic therapy...
5.
Jolly S, dEntremont M, Lee S, Mian R, Tyrwhitt J, Kedev S, et al.
N Engl J Med
. 2024 Nov;
392(7):633-642.
PMID: 39555823
Background: Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. Methods: In this multicenter trial with a 2-by-2 factorial...
6.
Jolly S, dEntremont M, Pitt B, Lee S, Mian R, Tyrwhitt J, et al.
N Engl J Med
. 2024 Nov;
392(7):643-652.
PMID: 39555814
Background: Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial after myocardial infarction is...
7.
Harel Z, Smyth B, Badve S, Blum D, Beaubien-Souligny W, Silver S, et al.
J Am Soc Nephrol
. 2024 Nov;
PMID: 39495569
No abstract available.
8.
Xie F, Yan J, Eikelboom J, Anand S, Muehlhofer E, Pullenayegum E, et al.
Eur Heart J Open
. 2024 Oct;
4(5):oeae083.
PMID: 39439530
Aims: This study aimed to compare the effects of the combination of rivaroxaban and aspirin with aspirin alone on health-related quality of life in the Cardiovascular Outcomes for People Using...
9.
Budgeon C, Nidorf S, Mosterd A, Fiolet A, Eikelboom J, OHalloran S, et al.
Am Heart J
. 2024 Sep;
278:186-194.
PMID: 39313104
Background: The Low Dose Colchicine 2 (LoDoCo2) trial randomized 5,522 patients with chronic coronary disease to colchicine 0.5mg daily or placebo in a 1:1 ratio and demonstrated the cardiovascular benefits...
10.
Haller P, Jarolim P, Palazzolo M, Bellavia A, Antman E, Eikelboom J, et al.
J Am Coll Cardiol
. 2024 Sep;
84(16):1528-1540.
PMID: 39230543
Background: Heart failure (HF) is common among patients with atrial fibrillation (AF), and accurate risk assessment is clinically important. Objectives: The goal of this study was to investigate the incremental...